References
1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal
cancer. Lancet 2019; 394:1467-80.
2. Yu Y, Nangia-Makker P, Farhana L, S GR, Levi E, Majumdar AP. miR-21
and miR-145 cooperation in regulation of colon cancer stem cells. Mol
Cancer 2015; 14:98.
3. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore
TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat
Immunol 2003; 4:63-8.
4. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK,
et al. IFN-lambdas mediate antiviral protection through a distinct class
II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
5. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB.
Interleukin-10 and related cytokines and receptors. Annu Rev Immunol
2004; 22:929-79.
6. Galani IE, Koltsida O, Andreakos E. Type III interferons (IFNs):
Emerging Master Regulators of Immunity. Adv Exp Med Biol 2015; 850:1-15.
7. Stanifer ML, Pervolaraki K, Boulant S. Differential Regulation of
Type I and Type III Interferon Signaling. Int J Mol Sci 2019; 20.
8. Broggi A, Tan Y, Granucci F, Zanoni I. IFN-lambda suppresses
intestinal inflammation by non-translational regulation of neutrophil
function. Nat Immunol 2017; 18:1084-93.
9. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C,
et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1
immune skewing and suppress allergic airway disease. EMBO Mol Med 2011;
3:348-61.
10. Misumi I, Whitmire JK. IFN-lambda exerts opposing effects on T cell
responses depending on the chronicity of the virus infection. J Immunol
2014; 192:3596-606.
11. Blazek K, Eames HL, Weiss M, Byrne AJ, Perocheau D, Pease JE, et al.
IFN-lambda resolves inflammation via suppression of neutrophil
infiltration and IL-1beta production. J Exp Med 2015; 212:845-53.
12. Good C, Wells AI, Coyne CB. Type III interferon signaling restricts
enterovirus 71 infection of goblet cells. Sci Adv 2019; 5:eaau4255.
13. Galani IE, Triantafyllia V, Eleminiadou EE, Koltsida O, Stavropoulos
A, Manioudaki M, et al. Interferon-lambda Mediates Non-redundant
Front-Line Antiviral Protection against Influenza Virus Infection
without Compromising Host Fitness. Immunity 2017; 46:875-90 e6.
14. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett
NW, et al. Role of deficient type III interferon-lambda production in
asthma exacerbations. Nat Med 2006; 12:1023-6.
15. Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA. Interferon
Lambda: Toward a Dual Role in Cancer. J Interferon Cytokine Res 2019;
39:22-9.
16. Yan Y, Wang L, He J, Liu P, Lv X, Zhang Y, et al. Synergy with
interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma
proliferation. Biomed Pharmacother 2017; 88:395-402.
17. Tezuka Y, Endo S, Matsui A, Sato A, Saito K, Semba K, et al.
Potential anti-tumor effect of IFN-lambda2 (IL-28A) against human lung
cancer cells. Lung Cancer 2012; 78:185-92.
18. Dai X, Lu L, Deng S, Meng J, Wan C, Huang J, et al. USP7 targeting
modulates anti-tumor immune response by reprogramming Tumor-associated
Macrophages in Lung Cancer. Theranostics 2020; 10:9332-47.
19. Majumder D, Debnath R, Maiti D. IL-27 along with IL-28B ameliorates
the pulmonary redox impairment, inflammation and immunosuppression in
benzo(a)pyrene induced lung cancer bearing mice. Life Sci 2020;
260:118384.
20. Farhana L, Sarkar S, Nangia-Makker P, Yu Y, Khosla P, Levi E, et al.
Natural agents inhibit colon cancer cell proliferation and alter
microbial diversity in mice. PLoS One 2020; 15:e0229823.
21. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB,
et al. An important role for type III interferon (IFN-lambda/IL-28) in
TLR-induced antiviral activity. J Immunol 2008; 180:2474-85.
22. Pearlman BL. The IL-28 genotype: how it will affect the care of
patients with hepatitis C virus infection. Curr Gastroenterol Rep 2011;
13:78-86.
23. Borden EC. Interferons alpha and beta in cancer: therapeutic
opportunities from new insights. Nat Rev Drug Discov 2019; 18:219-34.
24. Zanoni I, Granucci F, Broggi A. Interferon (IFN)-lambda Takes the
Helm: Immunomodulatory Roles of Type III IFNs. Front Immunol 2017;
8:1661.
25. Wang Y, Li T, Chen Y, Wei H, Sun R, Tian Z. Involvement of NK Cells
in IL-28B-Mediated Immunity against Influenza Virus Infection. J Immunol
2017; 199:1012-20.
26. Yan Y, Zhang J, Liu Y, Zhu T, Yuan L, Ge Y, et al. Inhibition of
lung adenocarcinoma transfected with interleukin 28A recombinant
adenovirus (Ad-mIFN-lambda2) in vivo. Cancer Biother Radiopharm 2013;
28:124-30.
27. Burkart C, Arimoto K, Tang T, Cong X, Xiao N, Liu YC, et al. Usp18
deficient mammary epithelial cells create an antitumour environment
driven by hypersensitivity to IFN-lambda and elevated secretion of
Cxcl10. EMBO Mol Med 2013; 5:1035-50.
28. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam
C, Takeda K, et al. NK cells require IL-28R for optimal in vivo
activity. Proc Natl Acad Sci U S A 2015; 112:E2376-84.
29. Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, et
al. Anti-tumor immunity elicited by direct intratumoral administration
of a recombinant adenovirus expressing either IL-28A/IFN-lambda2 or
IL-29/IFN-lambda1. Cancer Gene Ther 2016; 23:266-77.
30. Li Q, Kawamura K, Tada Y, Shimada H, Hiroshima K, Tagawa M. Novel
type III interferons produce anti-tumor effects through multiple
functions. Front Biosci (Landmark Ed) 2013; 18:909-18.
31. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, et
al. Antitumor activity of type I and type III interferons in BNL
hepatoma model. Cancer Immunol Immunother 2010; 59:1059-71.
32. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells
specifically induce proliferation of FOXP3-expressing suppressor T
cells. Blood 2006; 107:4417-23.
33. Zheng X, Turkowski K, Mora J, Brune B, Seeger W, Weigert A, et al.
Redirecting tumor-associated macrophages to become tumoricidal effectors
as a novel strategy for cancer therapy. Oncotarget 2017; 8:48436-52.
34. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of
apoptosis by type III interferons. Cell Prolif 2008; 41:960-79.
35. Zhou D, Huang C, Lin Z, Zhan S, Kong L, Fang C, et al. Macrophage
polarization and function with emphasis on the evolving roles of
coordinated regulation of cellular signaling pathways. Cell Signal 2014;
26:192-7.
36. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:
a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809.
37. Roca H, Craig MJ, Ying C, Varsos ZS, Czarnieski P, Alva AS, et al.
IL-4 induces proliferation in prostate cancer PC3 cells under
nutrient-depletion stress through the activation of the JNK-pathway and
survivin up-regulation. J Cell Biochem 2012; 113:1569-80.